Evaluation of the Safety and Effectiveness of CHORDS® Cerebral Protection System During TAVR: DUET Trial

Recruiting now · Not applicable

Conditions studied: Transcatheter Aortic Valve Replacement (TAVR), Cerebral Vascular Accident (CVA)/Stroke

In brief

This is a prospective, multi-center, randomized controlled study. The goal of the study is to assess the safety and effectiveness of the Resonova® CHORDS® Cerebral Protection System in capturing and removing embolic debris during Transcatheter Aortic Valve Replacement (TAVR). A total of 240 eligible participants will be enrolled and randomized in a 1:1 ratio to undergo TAVR either with the CHORDS® Cerebral Protection System (Test group) or the Sentinel System (Control group).All the participants will be followed up at 30 days and 90 days post-procedure.

Key facts

Study ID

NCT07648693

Run by

Resonova (Shanghai) Medtech Limited

People needed

240

Starts

2025-10-31

Expected to finish

2026-12-31

Last updated by the study team

2026-06-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or non-pregnant female, ≥18 years
• Patients with symptomatic severe aortic stenosis who are scheduled to undergo TAVR with commercialized transcatheter aortic valve system.
• Compatible left common carotid artery (6.5-10 mm) and brachiocephalic artery (9-15mm) diameters without significant stenosis (> 70%)
• Patients who are able to understand the study objectives, voluntarily participate, sign the informed consent form, and are willing to undergo required examinations and clinical follow-up.

You may not qualify if…

• General
• Contraindications to MRI, or planned implantation of an MRI-incompatible device at the index procedure, or planned implantation of an MRI-incompatible pacemaker or defibrillator within 30 days post-procedure.
• Acute myocardial infarction ≤ 30 days before the intended treatment
• Pure aortic regurgitation
• Pre-existing prosthetic aortic valve
• Echocardiographic evidence of intracardiac or aortic mass, thrombus, or vegetation
• Contraindication to antiplatelet and/or anticoagulant therapy, nitinol , or contrast media, or refusal to receive blood transfusions
• Vulnerable populations, including those unable to adequately understand the trial, those potentially subject to undue influence or coercion, those unable to complete the informed consent process, and those with severe disabling dementia or cognitive impairment Anatomic
• Vasculature (ie, right radial/brachial artery, carotid artery) precluding the device access
• Patients whose brachiocephalic or left carotid artery reveals significant stenosis（>70%）, ectasia, dissection, or aneurysm at the ostium or within 3 cm of the ostium

Where it is running

• Zhongshan Hospital, Fudan University — Shanghai, China (enrolling)
• Anhui Provincial Hospital — Hefei, Anhui, China (enrolling)
• Beijing Anzhen Hospital, Capital Medical University — Beijing, Beijing Municipality, China (enrolling)
• The First Affiliated Hospital of the Army Medical University of the Chinese People's Liberation Army — Chongqing, Chongqing Municipality, China (enrolling)
• Fujian Medical University Union Hospital — Fuzhou, Fujian, China (enrolling)
• The First Affiliated Hospital of Bengbu Medical College — Bengbu, Anhui, China (enrolling)
• Guangdong Provincial People's Hospital — Guangzhou, Guangdong, China (enrolling)
• Southern Medical University Nanfang Hospital — Guangzhou, Guangdong, China (enrolling)
• Sun Yat-sen Memorial Hospital of Sun Yat-sen University — Guangzhou, Guangdong, China (enrolling)
• The First Affiliated Hospital of Sun Yat-sen University — Guangzhou, Guangdong, China (enrolling)
• The First Affiliated Hospital of Nanchang University — Nanchang, Jiangxi, China (enrolling)
• Qingdao University Affiliated Hospital — Qingdao, Shandong, China (enrolling)
• West China Hospital, Sichuan University — Chengdu, Sichuan, China (enrolling)
• The First Affiliated Hospital of Wenzhou Medical University — Wenzhou, Zhejiang, China (enrolling)
• The First Affiliated Hospital of Fujian Medical University — Fuzhou, Fujian, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.